Comparing the effects of Ivy Extract and NAC in COPD patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of dry powder Ivy Extract (Syrup Prospan) compared to N-acetylcysteine (NAC) in patients with Chronic Obstructive Pulmonary Disease (COPD). It is a randomized, open-label interventional study where participants will be assigned to receive either Syrup Prospan or NAC for 30 days. The study will assess cough symptoms, health-related quality of life, and lung function before and after treatment. Participants will also provide feedback on their satisfaction with the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with documented post bronchodilator FEV1/FVC \< 70 or \<LLN
* Age 40 years and above
* Able to perform spirometry
* Participant with Stable COPD based on GOLD 2023 strategy

Exclusion Criteria:

* Diagnosis of other chronic lung diseases: Asthma, Asthma-COPD Overlap, Interstitial Lung Disease, Bronchiectasis, Lung Cancer
* Participants with contraindication for spirometry: recent cardiac complications, major surgery, severe advanced respiratory disease, or those with cognitively or neurologically impairment
* Hypersensitivity to acetylcysteine or any component of the formulation
* Hypersensitivity to dry powder ivy extract
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG (human Chorionic Gonadotropin) laboratory test
* Participant on pre-existing regular mucolytics (at least 1 month prior)
* Illiterate participants

Where it's running

• National University of Malaysia, Faculty of Medicine
  Cheras, Kuala Lumpur, Malaysia Recruiting
• National University of Malaysia
  Cheras, Kuala Lumpur, Malaysia Not yet recruiting

Study contacts

• Principal investigator: Mohamed Faisal Abdul Hamid, MBBS (IIUM) — National University of Malaysia
• Study coordinator: Mohamed Faisal Abdul Hamid, MBBS (IIUM)
• Email: faisal.hamid@ppukm.ukm.edu.my
• Phone: 0391455555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Flutter therapy added to chest physiotherapy after CABG in COPD patients

  This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.

  Recruiting Foundation University Islamabad · Rawalpindi · NCT07875049

• TPB-based cadence exercise and breathing training for COPD patients

  A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.

  Recruiting Fu Jen Catholic University Hospital · New Taipei City, New Taipei City and 1 other locations · NCT07860008

• See how dynamic chest X-rays relate to COPD patterns and progression risk

  This study looks at existing dynamic chest radiography data to see if new imaging measurements can identify COPD patterns, gauge severity, and predict who may experience faster progression.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07762573

• Personalized mobile app warnings to reduce COPD flares

  A personalized mobile app tests whether providing temperature-related risk warnings and protective tips, in addition to usual COPD care, can lower COPD flare-ups over 12 months.

  Recruiting at 4 sites Centers for Disease Control and Prevention, China · Beijing and 3 other locations · NCT07656142

• CLEAR model to predict when people with severe COPD can be taken off ventilatory support

  This project will see if the CLEAR model can predict which adults with severe COPD on invasive or non‑invasive ventilation can be safely taken off ventilatory support.

  Recruiting Assiut University · Asyut, Assuit Egypt · NCT07579052

• Long-term safety of Tozorakimab in COPD patients with prior exacerbations

  This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.

  Recruiting at 5 sites Phase 3 AstraZeneca · Aix-en-Provence and 12 other locations · NCT07566195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.